Tsimikas S - Search Results

1

Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.

Packard CJ, Pirillo A, Tsimikas S, Ference BA, Catapano AL. Packard CJ, et al. Among authors: tsimikas s. Cardiovasc Res. 2024 Feb 17;119(18):2843-2857. doi: 10.1093/cvr/cvad177. Cardiovasc Res. 2024. PMID: 38039351 Review.

2

Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.

Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Santos RD, et al. Among authors: tsimikas s. Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):689-99. doi: 10.1161/ATVBAHA.114.304549. Epub 2015 Jan 22. Arterioscler Thromb Vasc Biol. 2015. PMID: 25614280 Free PMC article.

3

Apolipoprotein C-III: From Pathophysiology to Pharmacology.

Norata GD, Tsimikas S, Pirillo A, Catapano AL. Norata GD, et al. Among authors: tsimikas s. Trends Pharmacol Sci. 2015 Oct;36(10):675-687. doi: 10.1016/j.tips.2015.07.001. Trends Pharmacol Sci. 2015. PMID: 26435212 Review.

4

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Graham MJ, Viney N, Crooke RM, Tsimikas S. Graham MJ, et al. Among authors: tsimikas s. J Lipid Res. 2016 Mar;57(3):340-51. doi: 10.1194/jlr.R052258. Epub 2015 Nov 4. J Lipid Res. 2016. PMID: 26538546 Free PMC article. Review.

5

Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.

Yeang C, Cotter B, Tsimikas S. Yeang C, et al. Among authors: tsimikas s. Cardiovasc Drugs Ther. 2016 Feb;30(1):75-85. doi: 10.1007/s10557-015-6634-1. Cardiovasc Drugs Ther. 2016. PMID: 26780907 Review.

6

The re-emergence of lipoprotein(a) in a broader clinical arena.

Tsimikas S. Tsimikas S. Prog Cardiovasc Dis. 2016 Sep-Oct;59(2):135-144. doi: 10.1016/j.pcad.2016.07.005. Epub 2016 Aug 3. Prog Cardiovasc Dis. 2016. PMID: 27497506 Review.

7

Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease.

Kothari H, Nguyen AT, Yang X, Hisada Y, Tsimikas S, Mackman N, Taylor A, McNamara CA. Kothari H, et al. Among authors: tsimikas s. J Cardiovasc Transl Res. 2018 Jun;11(3):221-229. doi: 10.1007/s12265-018-9790-4. Epub 2018 Jan 17. J Cardiovasc Transl Res. 2018. PMID: 29344841

8

Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.

Yeang C, Hasanally D, Que X, Hung MY, Stamenkovic A, Chan D, Chaudhary R, Margulets V, Edel AL, Hoshijima M, Gu Y, Bradford W, Dalton N, Miu P, Cheung DY, Jassal DS, Pierce GN, Peterson KL, Kirshenbaum LA, Witztum JL, Tsimikas S, Ravandi A. Yeang C, et al. Among authors: tsimikas s. Cardiovasc Res. 2019 Jan 1;115(1):179-189. doi: 10.1093/cvr/cvy136. Cardiovasc Res. 2019. PMID: 29850765 Free PMC article.

9

Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Tsimikas S. Tsimikas S. Circ Res. 2019 Feb;124(3):405-415. doi: 10.1161/CIRCRESAHA.118.313864. Circ Res. 2019. PMID: 30702993 Free PMC article. Review.

10

Lipid-Lowering Agents.

Hegele RA, Tsimikas S. Hegele RA, et al. Among authors: tsimikas s. Circ Res. 2019 Feb;124(3):386-404. doi: 10.1161/CIRCRESAHA.118.313171. Circ Res. 2019. PMID: 30702996

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

367 results

Search Page